DHHS

 

 

About the Program

• Program Overview
• Learning Objectives
• Course Directors
• Faculty for On-line Program
• On-Line Program Instructions for Participation and Credit
• Disclosure of Conflicts of Interest
• Accreditation Statement -ACCME
• Credit Designation - ACCME
• Accreditation Statement - ACPE
• Credit Designation - ACPE
• Faculty Financial Disclosures
• PIM Financial Disclosures
• Request for Program Slides and Review 

Program Overview

In 1996, the Department of Health and Human Services (DHHS) introduced "Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents" (the "Guidelines"), written by the Panel on Clinical Practices for Treatment of HIV Infection (the "Panel"). These Guidelines are heavily used by clinicians to construct effective ARV regimens that extend and improve the lives of HIV-positive patients. The Guidelines attempt to keep pace with the rapid changes that occur in HIV treatment, and, as new data are presented and published, the Panel issues a revision of the Guidelines. The Panel issued the latest update of the Guidelines on December 1, 2009. This informative and enjoyable series will help to educate clinicians caring for HIV-positive patients regarding the important updates to the Guidelines and how these changes to the Guidelines should affect or influence their clinical practice.

Target Audience

This tuition-free program has been designed to meet the educational needs of health care providers, including physicians, physician assistants, nurse practitioners, and pharmacists, who treat HIV-positive patients and there are no prerequisites. (ACCME and ACPE credits are awarded.)

Back to Top

Learning Objectives

Upon completion of the program, participants should be able to:

1. Describe the ARV therapy guidelines in the Department of Health and Human Services "Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents".

2. Discuss important revisions made in the recently updated Department of Health and Human Services "Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents".

3. Explain the relevant clinical studies and data cited by the panel as the reasons for making recent revisions to the Department of Health and Human Services "Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents" .

4. List key issues covered by the Department of Health and Human Services "Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents" and how these should affect the clinical care of HIV-positive patients . 

Back to Top

Course Directors

..	John Bartlett, MD Professor of Medicine, Johns Hopkins School of Medicine Baltimore, Maryland
..	Calvin J. Cohen, MD, MS Research Director, CRI New England Clinical Instructor, Harvard Medical School Boston, Massachusetts

Back to Top  

Faculty for On-line Program 

..	Sujata Ambardar, MD Section Chief, Infectious Disease Department Inova Fairfax Hospital Infectious Diseases Physicians, Inc. Annandale, Virginia	...	..	Trevor Hawkins, MD Associate Professor, University of New Mexico Medical Director, Southwest CARE Center Santa Fe, New Mexico
..	Edwin DeJesus, MD Medical Director, Orlando Immunology Center Orlando, Florida		..	Michael Sension, MD Medical Director, HIV Clinical Research, Broward Health Ft. Lauderdale, Florida
..	Richard A. Elion, MD Associate Professor of Clinical Medicine, George Washington University Medical Center Washington, DC		..	Glenn Treisman, MD Professor & Director, AIDS Psychiatric Services, Johns Hopkins University School of Medicine Baltimore, Maryland
..	Joseph Eron, MD Professor University of North Carolina School of Medicine Chapel Hill, North Carolina		..	Luther A. Virgil, Jr., MD Chief Medical Officer, National Minority Clinical Research Association (NMCRA) Fairfield, New Jersey
..	Ian Frank, MD Professor of Medicine, Director, Antiretroviral Clinical Research, University of Pennsylvania Philadelphia, Pennsylvania

Back to Top 

On-Line Program Information

 

Instructions for On-Line Participation and Credit

There are no fees for participating and receiving credit for these activities. During the period, December 15, 2009 through December 15, 2010, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question in the answer key on the evaluation form; and 4) complete the Evaluation form.

You may complete the Post-test on-line at www.cmeuniversity.com.

• Click on "Find Post-Test/Evaluation by Course" on the navigation menu
• Search by project ID 6983
• Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), ViralEd, LLC, and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ViralEd, LLC, and Merck & Co., Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top  

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top

Accreditation Statement (ACCME)

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ViralEd. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation (ACCME)

Postgraduate Institute for Medicine designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Back to Top

Accreditation Statement (ACPE)

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Back to Top

Credit Designation (ACPE)

Postgraduate Institute for Medicine designates this continuing education activity for 2.75 contact hour(s) (0.275 CEUs) of the Accreditation Council for Pharmacy Education. If you have participated and claimed credit for the live activity titled The Updated DHHS Guidelines: A Critical Review and Discussion of What's New and Important - Live Lecture Program, UAN 0809-9999-10-007-L02-P, you are not eligible to claim credit for this activity.

Type of Activity - Knowledge

Back to Top

Faculty Financial Disclosures

Sujata Ambardar, MD:

• No real or apparent conflicts of interest to report  

Calvin Cohen, MD, MS:

• Sources of Funding for Research: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Pfizer; Tibotec.
• Consulting Agreements: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Pfizer; Tibotec.
• Speakers' Bureau: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Tibotec.

Edwin DeJesus, MD:

• Sources of Funding for Research: Boehringer Ingelheim; Abbott; Achillion; Avexa; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Hoffman LaRoche; Pfizer; Merck & Co; Schering-Plough; Taimed; Tobira; Tibotec; Vertex.
• Consulting Agreements: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck & Co.; Tibotec; Vertex Pharmaceuticals.
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck & Co.; Tibotec; Vertex Pharmaceuticals; Virco.

Richard Elion, MD:

• Sources of Funding for Research: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck & Co.; Rapid; Tibotec.
• Consulting Agreements: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Tibotec.

Joseph Eron, MD:

• Sources of Funding for Research: GlaxoSmithKline; Panacos; Merck & Co.; TaiMed.
• Consulting Agreements: Merck & Co.; Avexa; Bristol-Myers Squibb; GlaxoSmithKline; Tibotec; Virco Laboratories; Pfizer; Tobira; Chimerix; Myriad.
• Speakers' Bureau/Honorarium Agreements: Roche; Bristol-Myers Squibb; Tibotec (Not active since 1/1/09); Virco laboratories; Gilead Sciences (Not active).

Ian Frank, MD:

• Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Pfizer.
• Speakers' Bureau: Bristol-Myers Squibb; Gilead Sciences; Tibotec.

Trevor Hawkins, MD:

• Sources of Funding for Research: Gilead Sciences; GlaxoSmithKline; Pfizer; Salix.
• Consulting Agreements: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead Sciences; Pfizer; Tibotec.

Michael Sension, MD:

• Consulting Agreements: Gilead Sciences; Tibotec.
• Speakers' Bureau/Honorarium Agreements: Bristol-Myers Squibb; Gilead Sciences; Merck & Co.; Tibotec.  

Glenn Treisman, MD:

• Speakers' Bureau/Honorarium Agreements:Boehringer Ingelheim.

Luther Virgil, MD:

• No real or apparent conflicts of interest to report.

Back to Top  

PIM Financial Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers: Jan Hixon, RN, BSN, MS, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.

Back to Top

Request for Program Slides and Review 

To request a copy of the program slides as well as further education on how to use the slides please Click Here to fill out a content request form.  

Back to Top

 

 

 

All programs will be available at www.viraled.com

Supported by an unrestricted educational grant from Merck & Co., Inc.

Share this page:

                     

<a href="http://www.viraled.com/modules/info/dhhs.html" title="DHHS">DHHS</a>